Peer Reviewed Publications
Deerland makes significant investments in clinical research to support the safety and efficacy of its probiotic, prebiotic and enzyme-based branded ingredients.
Bacillus subtilis DE111® Clinical Studies
More than 30 studies have been performed to confirm the safety and efficacy of Bacillus subtilis DE111. A full genome sequencing confirmed the strain contained no plasmids, antibiotic resistant or deleterious genes.
Germination and Functional Properties
- Colom et al 2021. Presence and Germination of the Probiotic Bacillus subtilis DE111® in the Human Small Intestinal Tract
- Mazhar et al 2023. In vitro and in silico assessment of probiotic and functional properties of Bacillus subtilis DE111®
Digestion
- Labellarte, G. and Maher, M. 2019. Tolerance and Effect of a Probiotic Supplement Delivered in Capsule Form.
Regularity
- Cuentas, et al. 2017. The Effect of Bacillus subtilis DE111 on the Daily Bowel Movement Profile for People with Occasional Gastrointestinal Irregularity
Immune Health
- Freedman, et al. 2021. Examining the Gastrointestinal and Immunomodulatory Effects of the Novel Probiotic Bacillus subtilis DE111
Sports Performance, Body Composition and Recovery
- Toohey, Townsend, et al. 2018. Effects of Probiotic (Bacillus subtilis) supplementation during offseason resistance training in female division I athletes
- Townsend, et al. 2018. Effects of Probiotic (Bacillus subtilis DE111) Supplementation on Immune Function, Hormonal Status, and Physical Performance in Division I Baseball Players
Cardiovascular Health
- Trotter, et al 2020. Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults
Children’s Microbiome & Immune Health
- Paytuvi-Gallart et al. 2020. Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care
- Slivnik et al. 2020. Effect of Daily Bacillus subtilis DE111® Intake on Gastrointestinal Health and Respiratory Infections in Children Attending Day-care: A Randomised, Parallel, Double-blind, Placebo-controlled Study
ProHydrolase Clinical Studies
Numerous in vitro studies plus two separate human clinical studies have shown the superior ability of ProHydrolase to quickly break down protein, increase available amino acids in the blood, decrease C-reactive protein levels and decrease the large peptides associated with stomach discomfort that results from consuming protein.
PreForPro® Clinical Studies
More than 20 studies have been performed to confirm the safety and efficacy of PreforPro. In-vitro and in-vivo tests have demonstrated the growth-promoting effect of PreforPro on beneficial bacterial strains of Lactococcus, Lactobacillus, Bifidobacterium and Bacillus subtilis when competing with undesirable bacterial strains. In a human clinical study, PreforPro was shown to influence the microbial population of the gut, without disrupting the global microbiota.
- Gindin et al. 2018. Bacteriophage for Gastrointestinal Health (PHAGE) Study: Evaluating the Safety and Tolerability of Supplemental Bacteriophage Consumption
- Grubb et al. 2020. PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults
- Febvre et al. 2019. PHAGE Study: Effects of Supplemental Bacteriophage Intake on Inflammation and Gut Microbiota in Healthy Adults
Glutalytic Clinical Studies
Numerous in vitro studies plus two separate human clinical studies have shown the superior ability of Glutalytic to quickly break down gluten proteins, effectively reducing the frequency and severity of symptoms associated with gluten sensitivity. Glutalytic is also clinically proven to reduce levels of IgA and CRP, supporting a proper immune response.
- Maher et al. 2018. A Glutalytic Enzyme Supplement Was Tolerated by Healthy Young Adults
- Deaton et al. 2018. Tolerance and Efficacy of Glutalytic™: A Randomized, Double-Blind, Placebo-Controlled Study
EcoVag Clinical Studies
- Daskalakis, Karambelas 2016.Vaginal Probiotic Administration in the Management of Preterm Premature Rupture of Membranes
- Larsson et al. 2008. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study
- Pendharkar et al. 2015. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses
- Keller et al. 2017. Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection”
Additional Published Studies
Siebeneicher, Deaton, et al. 2018. Validation of a Competitive Elisa Method on Supplemental Enzyme Matrices
